|

Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

RECRUITINGSponsored by Jinling Hospital, China
Actively Recruiting
SponsorJinling Hospital, China
Started2022-12-26
Est. completion2028-06
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05917106

Summary

To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Newly diagnosed renal cell carcinoma
* Without any treatment
* Agree and accept radical surgical treatment
* Signed written informed consent
* ECOG(Eastern Cooperative Oncology Group) performance is 0 or 1
* Follow up protocol and related procedures

Exclusion Criteria:

* Had other cancers
* Had received any antitumor therapy before
* Known or suspected active autoimmune disease
* Informed consent is not possible due to medical or psychiatric problems
* Have clinical symptoms or diseases of the heart that are not well controlled
* Patients judged by the investigators to be unsuitable for inclusion in this study

Conditions6

CancerCarcinomaKidney CancerKidney NeoplasmsRCCRenal Cell Carcinoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.